These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11779761)

  • 1. Intravenous immunoglobulins control scleromyxoedema.
    Righi A; Schiavon F; Jablonska S; Doria A; Blasczyk M; Rondinone R; Todesco S; Matucci Cerinic M
    Ann Rheum Dis; 2002 Jan; 61(1):59-61. PubMed ID: 11779761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case 5: extensive skin eruption causing skin to become tight, sore, and itchy. Diagnosis: scleromyxoedema.
    Karim A; Black MM; Lawlor F
    Clin Exp Dermatol; 2003 May; 28(3):343-4. PubMed ID: 12780738
    [No Abstract]   [Full Text] [Related]  

  • 3. Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin.
    Shergill B; Orteu CH; McBride SR; Rustin MH
    Br J Dermatol; 2005 Sep; 153(3):650-2. PubMed ID: 16120159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin.
    Karim A; Lawlor F; Black MM
    Clin Exp Dermatol; 2004 May; 29(3):317-8. PubMed ID: 15115524
    [No Abstract]   [Full Text] [Related]  

  • 5. High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system.
    Guarneri A; Cioni M; Rongioletti F
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1157-1160. PubMed ID: 28370513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin.
    Kulczycki A; Nelson M; Eisen A; Heffernan M
    Br J Dermatol; 2003 Dec; 149(6):1276-81. PubMed ID: 14674909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of intravenous immunoglobulin in the treatment of scleromyxoedema].
    Sillard L; Passeron T; Cardot-Leccia N; Perrin C; Lacour JP; Ortonne JP
    Ann Dermatol Venereol; 2010 Jan; 137(1):48-52. PubMed ID: 20110069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Koebner phenomenon due to scratch test in scleromyxoedema.
    Durani BK; Kurzen H; Hartschuh W; Naeher H
    Br J Dermatol; 2001 Aug; 145(2):306-8. PubMed ID: 11531798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin.
    Körber A; Franckson T; Grabbe S; Dissemond J
    J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):553-4. PubMed ID: 17373996
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulins.
    Wojas-Pelc A; Błaszczyk M; Glińska M; Jabłońska S
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):462-5. PubMed ID: 15987294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of high-dose intravenous immunoglobulin treatment of patients with pretibial myxedema and Basedow's disease. Preliminary findings].
    Antonelli A; Saracino A; Agostini S; Alberti B; Melosi A; Gambuzza C; Avantaggiato G; Baschieri L
    Clin Ter; 1992 Sep; 141(9 Pt 2):63-8. PubMed ID: 1281765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scleromyxoedema-like changes in four renal dialysis patients.
    Hubbard V; Davenport A; Jarmulowicz M; Rustin M
    Br J Dermatol; 2003 Mar; 148(3):563-8. PubMed ID: 12653751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Internal disease findings in Arndt-Gottron scleromyxedema].
    Lang E; Goos M
    Dtsch Med Wochenschr; 1986 May; 111(21):820-3. PubMed ID: 3084193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes.
    Bidier M; Zschoche C; Gholam P; Enk AH; Hadaschik EN
    Acta Derm Venereol; 2012 Jul; 92(4):408-9. PubMed ID: 22278389
    [No Abstract]   [Full Text] [Related]  

  • 15. Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins.
    Gholam P; Hartmann M; Enk A
    Br J Dermatol; 2007 Nov; 157(5):1058-60. PubMed ID: 17854360
    [No Abstract]   [Full Text] [Related]  

  • 16. Dermato-neuro syndrome after COVID-19 infection in a patient with scleromyxoedema: Previously successful treatment with intravenous immunoglobulins.
    Li Y; Wang H; Wang A; Zhao G
    J Dermatol; 2024 Jan; 51(1):140-144. PubMed ID: 37830263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scleromyxoedema--successful treatment with plasma exchange and immunosuppression.
    Macfarlane AW; Davenport A; Verbov JL; Goldsmith HJ
    Br J Dermatol; 1987 Nov; 117(5):653-7. PubMed ID: 3689684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease.
    Bounfour T; Bouaziz JD; Bézier M; Cordoliani F; Saussine A; Petit A; Juillard C; Bagot M; Rybojad M
    J Eur Acad Dermatol Venereol; 2014 Sep; 28(9):1150-7. PubMed ID: 23906502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus.
    Sherer Y; Shoenfeld Y
    Autoimmun Rev; 2006 Feb; 5(2):153-5. PubMed ID: 16431350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An intravenous immunoglobulin therapy of serious autoimmune rheumatic diseases.
    Lukan N; Lazurova I; Racz O; Kristofova B; Tkac I
    Bratisl Lek Listy; 2008; 109(11):489-92. PubMed ID: 19205557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.